Delivery Order SPE2DB20D2104-SPE2DB25FMXWT
- Not listed
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $2,448.81 by the Defense Logistics Agency (DLA) on July 14, 2025, for the supply of Mounjaro 12.5 mg/0.5 mL pen injections. This contract represents a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The contract is scheduled for ultimate completion by July 15, 2025, with performance taking place at the...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $28,786.43 by the Defense Logistics Agency on September 18, 2025, for the supply of Mounjaro 5 mg/0.5 ml pen injectors (0.5 ml). This competitive, firm fixed-price delivery order is non-set-aside and is scheduled for completion by September 19, 2025, with performance taking place at the company's corporate office location in Conshohocken,...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $25,619.20 by the Defense Logistics Agency on July 18, 2025, for the supply of Mounjaro 5 mg/0.5 mL pen injectors. This firm fixed-price delivery order, which carries an ultimate completion date of July 21, 2025, represents a non-competitive set-aside transaction and will be performed at the company's Corporate Office location in Conshohocken, PA....
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on September 11, 2025, for the supply of Mounjaro 7.5 mg/0.5 mL pen injections, with a contract ceiling value of $1,597.14 and an ultimate completion date of September 12, 2025. This is a firm fixed-price delivery order with no set-aside designation, awarded competitively under open competition. The place of performance is located at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania....
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $1,088.36 for Mounjaro 15 mg/0.5 mL pen injections on June 16, 2025, with an ultimate completion date of June 17, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract vehicle with DLA Troop Support Medical (SPE2DX), valued at approximately $1...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency on May 7, 2025, for the supply of Mounjaro 7.5 mg/0.5 mL pen injectors valued at $27,363.70, with completion scheduled for May 8, 2025. The order represents a firm fixed-price, competitively awarded delivery against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. Performance will be...
- The Defense Logistics Agency awarded a delivery order valued at $1,825.26 to AmerisourceBergen Drug Corp for the supply of Mounjaro 5 mg/0.5 ml pen injectors on August 13, 2025, with completion scheduled for August 14, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion pharmaceutical supply vehicle running through December 2026. The...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $8,162.70 by the Defense Logistics Agency on September 18, 2025, for the supply of Mounjaro 7.5 mg/0.5 mL pens. The contract is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. Performance will be completed by September 19, 2025, with the place of performance located in Conshohocken,...
- The Defense Logistics Agency awarded a $5,652.64 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Mounjaro 7.5 mg/0.5 mL pen injectors with an ultimate completion date of September 8, 2025. This non-set-aside contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract action under AmerisourceBergen's substantial Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Mounjaro 10 mg/0.5 ml pen injections valued at $7,989.68. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 12, 2025, with performance taking place at AmerisourceBergen's Conshohocken, Pennsylvania facility. The contract carries no set-aside designation, reflecting the contractor's demonstrated capability to compete in...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FMXWTDelivery Order
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency (DLA) on August 14, 2025, for the supply of Mounjaro 5 mg/0.5 mL pen injections. The contract, valued at $20,199.71, is a firm fixed-price delivery order with an ultimate completion date of August 15, 2025. This award was made on a competitive basis with no set-aside designation and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. The delivery order supports the Department of Defense's medical supply chain operations and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Mounjaro, a diabetes medication, falls within the pharmaceutical product categories that AmerisourceBergen regularly supplies to federal healthcare systems, including the Defense Health Agency and U.S. Coast Guard, through its comprehensive global pharmaceutical prime vendor vehicle. This transaction exemplifies the company's role as a critical medical supplier supporting military healthcare programs through the DLA's pharmaceutical procurement initiatives.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $20.2k | 8/14/25 |